MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently advancing DA-1726 for the treatment of obesity and vanoglipel for MASH.
The net loss was $7.35 per basic and diluted share for 2025, compared to a net loss of $39.13 per share in 2024.
Total operating expenses decreased to $13.7 million in 2025, down from $28.8 million in 2024. MetaVia concluded the year with $10.3 million in cash and cash equivalents.
This article was generated with the assistance of AI technology and reviewed for accuracy. AlphaStreet may receive compensation from companies mentioned in this article. This content is for informational purposes only and should not be considered investment advice.
The post MetaVia (MTVA) 2025 Financial Update first appeared on Alphastreet.
